International Multicentric Pooled Analysis of Colon Cancer Trials Investigators, IMPACT: Efficacy of adjuvant 5FU and folinic acid in colon cancer.Lancet, 345: 939–944, 1995.
2.
AndreT., BoniC., Mounedji-BoudiafL.: Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer.NEJM, 350: 2343–2351, 2004.
3.
GrayR.G., BarnwellJ., HillsR.: QUASAR, a randomized study of adjuvant chemoterapy vs observation including 3238 colorectal cancer pts.Proc ASCO, abst 3501, 2004.
4.
WolmarkN., WieandS., LemberskyB.: A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of the NSABP protocol C-06.Proc ASCO, abst 3508, 2004.
5.
CassidyJ., ScheithauerW., McKendrickG.: Capecitabine (X) vs bolus 5FU/LV as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial.Proc ASCO, abst 3509, 2004.
6.
AndrèT., ColinP., LouvetC.: Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant treatment in stage II and III colon cancer: results of a randomized trial.J Clin Oncol, 21: 2896–2903, 2003.
7.
ScheitauerW., McKendrickJ., BegbieS.: Oral capecitabine as an alternative to iv 5-FU-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.Ann Oncol, 14: 1735–1743, 2003.
8.
CassidyJ., TwelvesC., Van CutsemE.: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-FU/LV.Ann Oncol, 13: 566–575, 2002.
9.
McKendrickJ., CassidyJ., ChakrapeeS.: Capecitabine is resource saving compared with iv bolus 5FU/LV in adjuvant chemotherapy for Dukes’ C colon cancer patients: medical resource utilization (MRU) data from a large phase III trial (X-ACT).Proc ASCO, abst 3578, 2004.
